Drug-Development Cycle Acceleration

What happens when AI models become as trustworthy as clinical data? The answer could redefine drug development entirely: Drug development has always followed the same path: discovery, preclinical, clinical, regulatory, launch. Each phase took years, each step consumed capital. AI is now reshaping that entire cycle. Not just how drugs are discovered, but how they’re tested, approved, and commercialized. 1. Discovery: Faster Target-to-Candidate Nearly 30% of new preclinical candidates now come from AI pipelines. Platforms like Atomwise, BenevolentAI, and Insilico Medicine combine genomics and chemistry data to find targets, design molecules, and predict interactions. Discovery timelines are dropping up to 40%, costs by 30%. Partnerships such as AstraZeneca’s $555M deal with Algen Biotech show the shift from single assets to scalable discovery systems. 2. Preclinical: Reducing Animal Testing The FDA Modernization Act (2022) authorized AI toxicity and organ-on-chip models as non-animal alternatives. By 2025, pilot IND programs now accept validated AI and organ-chip data, removing months from preclinical cycles. Earlier go/no-go decisions and better human relevance are driving faster IND readiness. 3. Clinical: From Months to Weeks AI accelerates recruitment, site selection, and adaptive design. Patient matching that once took months now happens in days. Digital-twin models reduce participants while maintaining statistical power. FDA’s 2025 guidance defines how “AI model credibility” must be proven: clear context, explainability, and monitoring. Experts expect clinical programs 30–50% shorter by 2030. Could regulators ever skip Phase 1 studies if AI models predict safety and dose outcomes? Not yet, but hybrid models pairing AI evidence with smaller human trials are emerging. 4. Regulatory and Launch AI already supports dossier preparation, evidence synthesis, and risk analysis. Regulators now expect transparent validation and lifecycle monitoring for any AI used in submissions. Commercially, AI drives forecasting, access strategy, and post-market analytics. By 2030, it may function as the operating system for commercialization itself. 5. Proprietary vs Open AI Pharma is dividing. Some build closed, proprietary models for control and IP protection. Others favor open frameworks for speed and collaboration. The likely future is hybrid: closed models refined on private data, open components for discovery and interoperability. Computational evidence is becoming as strategic as clinical data. 3 Signals for Executives: • Is your team treating AI as core infrastructure, not a pilot? • Are you investing in regulatory-grade model validation and lifecycle monitoring? • Is your platform strategy built for transparency and collaboration with regulators and partners? At Kybora.com, we help leaders navigate this transformation, aligning science, capital, & execution in the AI-enabled future of biopharma.

Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization Hit-to-lead is often where drug discovery slows down: chemists have a few “hits” and then spend months tweaking structures, running reactions that may or may not work, and testing compounds one by one. The real bottleneck isn’t ideas for new analogues—it’s synthesizing the right ones fast enough with limited time and material. David Nippa and colleagues show a different way to work: start by teaching a model chemistry. They first used miniaturized high-throughput experimentation to run 13,490 Minisci C–H alkylation reactions, then trained graph neural networks to predict which late-stage alkylations will actually work, and with what yield. On top of this, they built a “machine learning funnel” that enumerates virtual analogues, predicts how well each might bind the target (MAGL, a CNS-relevant enzyme), checks synthetic feasibility via reaction prediction, and filters on key ADME properties—all before anyone walks into the lab. The scale is striking: 125 MAGL hits × 211 carboxylic acids → 26,375 virtual products. The ML funnel narrowed this to 212 promising, synthesizable candidates; chemists then used miniaturized screening to optimize conditions and scaled up just 14 compounds. Every single one was more potent than the original hit, with some showing up to 4,500-fold improvement and sub-nanomolar activity, while maintaining favorable permeability, solubility, and lipophilic efficiency. Co-crystal structures confirmed that the new substituents exploit previously unused pockets in the binding site. Perhaps most impressive is the timeline: one integrated cycle—virtual library, docking, reaction prediction, property filtering, HTE optimization, scale-up, and biological testing—completed in about a month. This paper is a concrete example of how coupling FAIR reaction data, geometric deep learning, and late-stage functionalization can turn hit-to-lead from a slow, artisanal process into an accelerated, data-driven pipeline. Paper: https://lnkd.in/dv3m2p3J #MachineLearning #DrugDiscovery #MedicinalChemistry #AIforScience #Cheminformatics #ComputationalChemistry #ReactionOptimization #HitToLead #LateStageFunctionalization #OrganicChemistry #DataDrivenScience #MLInChemistry #AIInDrugDiscovery #ChemicalBiology #PharmaceuticalResearch

One of the most interesting shifts in pharma R&D right now is the emergence of continuous learning loops between computational models and lab experiments. Strategic investments are reinforcing this direction. A recent example is the $1B collaboration between NVIDIA and Eli Lilly and Company, aimed at building an AI factory for drug discovery, leveraging large-scale models trained on the language of biology and chemistry. At the core of this approach is a tight feedback loop between the wet lab and the dry lab, where experimental results continuously update computational models. Instead of the traditional discovery cycle: Hypothesis → experiment → analysis → new hypothesis AI enables something closer to: Model prediction → experiment → real-time data → updated model → next experiment This continuous loop allows research teams to iterate far more quickly. Industry analyses suggest that embedding AI directly into experimental workflows could reduce discovery timelines by as much as 40% in some cases. For pharma organizations, the implications are significant: • accelerating target validation • prioritizing experiments more effectively • reducing failed experimental cycles The companies that succeed may not simply use AI tools. They will build AI-native discovery systems in which computation and experimentation continuously inform one another. Article: https://lnkd.in/gzXqtj2Y #AI #DrugDiscovery #Pharma #Biotech #PrecisionMedicine#AI #DrugDiscovery #Biotech #PharmaR&D

We’ve optimized everything around the trial — except the documents that govern it. That blind spot is exactly where new AI-first players are gaining ground. In a world where trial documentation, regulatory compliance, and study-start-up workflows remain painfully manual, companies like Cori Clinical are rewriting the rules. They bring AI and automation directly into the heart of trial-planning and documentation — accelerating timelines while preserving compliance and control. ✅ AI-assisted drafting and co-authoring of protocols, investigator brochures, informed-consent forms, site-packs, SOPs — going from weeks to minutes. ✅ Regulatory-ready review & compliance checks: AI flags potential compliance or GxP issues, quality and patient-focus requirements — reducing risk and manual burden. ✅ Automated amendment & version control + audit-ready documentation — simplifying management across multiple trial sites and stakeholders. ✅ Workflow integration — works directly with tools like Microsoft Word and Veeva, preserving familiar workflows for teams while adding automation. For biotech, pharma and med-device sponsors — especially smaller or emerging companies — this kind of “clinical-grade AI workbench” can dramatically reduce time, cost, and administrative overhead. As the industry increasingly moves toward modular, tech-enabled services, the shift will reward teams that build flexible, automation-ready workflows capable of scaling across diverse trial portfolios. #ClinicalDevelopment #LifeSciencesAI #DigitalTrials #ClinicalOperations #AIDrivenInnovation #DrugDevelopment #PharmaTech #ClinicalResearch #R&DTransformation #HealthTech

Machine Learning in Preclinical Drug Discovery 🧬💊 Machine learning (ML) is increasingly integrated into preclinical drug discovery, offering promising advancements across hit identification, mechanism-of-action elucidation, and translational investigations. A recent paper in Nature Chemical Biology, "Machine Learning in Preclinical Drug Discovery", provides a thorough analysis of how ML is being utilized to enhance efficiency in early-stage drug development. 🔬 Key Insights from the Paper 1️⃣ Hit Identification & Virtual Screening Traditionally, high-throughput screening (HTS) has been the gold standard for identifying potential drug candidates. However, it is resource-intensive and slow. ML-based virtual screening, powered by deep learning models and molecular featurization techniques, is enabling rapid exploration of chemical libraries far beyond what traditional HTS can achieve. The paper highlights the impact of message-passing neural networks (MPNNs) and Deep Docking as effective methods for prioritizing hit compounds. 2️⃣ Mechanism-of-Action (MOA) Elucidation Understanding how a compound interacts with biological targets is critical for drug development. ML is now playing a pivotal role in MOA elucidation through: AlphaFold and RoseTTAFold: AI-driven protein structure prediction is accelerating target identification and binding site analysis. Generative models: Variational autoencoders (VAEs) and diffusion models are not only aiding in de novo drug design but also helping predict chemical interactions with biological systems. 3️⃣ Translational Investigations & ADMET Predictions Many promising compounds fail in later stages due to poor pharmacokinetics and toxicity profiles. ML is being leveraged to enhance ADMET predictions, improving the likelihood of clinical success. The paper discusses advancements in: Solubility and Lipophilicity Predictions: ML-driven models now outperform traditional log(P) estimations, increasing the reliability of early-stage compound selection. Toxicity Screening: AI-powered tools are improving predictions of hERG binding and organ toxicity, reducing late-stage failures. 🚀 The Future of AI in Drug Discovery While ML is proving to be a game-changer, challenges remain, including data quality, interpretability of AI models, and integration with experimental validation. The paper underscores the importance of open-source datasets, AI transparency, and active learning strategies to enhance model accuracy. 🔗 Read the full paper here: https://lnkd.in/gMtXHrHi AI is reshaping the landscape of drug discovery. As these technologies evolve, collaboration between computational scientists, biologists, and chemists will be critical to unlocking their full potential. #AI #MachineLearning #DrugDiscovery #Pharma #Biotech #ArtificialIntelligence #ComputationalBiology #NatureChemicalBiology

📢 A new paper suggests that a plain-language text prompt may soon be enough to launch an end-to-end drug discovery program... In a new paper, co-authored by Alex Zhavoronkov and David Gennert, PhD, (Insilico Medicine) and Jiye Shi (Eli Lilly and Company), researchers conceptualize a drug discovery paradigm in which a text prompt can initiate an end-to-end drug development program, from target discovery to a clinical-ready candidate. In "From Prompt to Drug: Toward Pharmaceutical Superintelligence", the authors describe how modern drug discovery already can benefit from AI at nearly every step, including omics-driven target identification, generative molecular design, docking and ADMET prediction, retrosynthesis planning, automated synthesis, and even clinical trial modeling. ☝ The problem, they argue, is not a lack of capability but a lack of integration. These systems operate in silos, with humans coordinating handoffs between tools, labs, and teams, creating delays, errors, and bias. Their proposed solution is an AI-orchestrated "system-of-systems". Large language models with advanced reasoning capabilities act as central controllers: planning workflows, coordinating specialized AI agents, calling physics-based models (molecular dynamics, docking, QM), and interfacing with automated laboratories via APIs. Rather than generating molecules directly and hoping for the best, the system runs closed-loop design–make–test–analyze cycles, where experimental results continuously feed back into model refinement. The paper is explicit about technical constraints, though. LLMs alone lack biochemical grounding, suffer from hallucinations, and can propagate errors across pipeline stages. To mitigate this, the authors emphasize hybrid architectures combining language-based planning with structure-aware models, ensemble validation between agents, confidence propagation, backtracking, and mandatory human-in-the-loop checkpoints for high-stakes decisions such as clinical trial design. They refer to the long-term outcome as Pharmaceutical Superintelligence. It is not a single model, but a coordinated, multimodal platform trained on omics data, molecular structures, experimental results, and clinical outcomes, capable of autonomously running large portions of drug discovery while remaining auditable and regulator-aligned. It is a thought-provoking read, and I am curious to read your thoughts about it. While the idea might seem futuristic to some, Insilico Medicine demonstrated a track record of fast-paced drug discovery programs reaching clinical milestones... so while none of their programs are FDA approved yet, they are certainly trying hard to build this vision, it seems... time will tell. Image credit: authors of the paper

Must-read for those trying to understand Chinese biotech innovation, and how it modernized so quickly. Arkhisa Mukherjee details the reorganization of the regulatory process in China that now allows vastly faster clinical trials and drug approvals. " By verifying internal regulatory documents and synthesizing external market data, we dissect the seven structural pillars of the “Accelerationist State” and project the consequences of a world where the East no longer waits for the West’s medicine. " Mukherjee then lists the pillars: * Acceleration by design: speed as a Legal obligation. China codified 60 day silent approval for Clinical Trial Applications. No response is a green light. * Capacity scaled before speed demanded. China increased headcount for regulatory agency from 200 to 1300 staff (550%) increase by 2019 all in ANTICIPATION of global stampede for clinical testing in China. * " China last " to China first... Before 2018, China required independent clinical trials in China for external drugs and drug candidates. This policy slowed down access to western drugs by years. But by following ICH, China has adopted global industry standards on GCP so former barriers were greatly reduced. This speed has also allowed a China-first approach to clinical approval, potentially reaching the domestic market years ahead of Western markets. * Incentives aligned end-to-end. Government and private co-funding of clinical research has greatly widened the entry of molecules being tested in clinic. In addition accelerated approvals to under six months under priority status within their regulatory process. Approved drugs enjoy a 5 year barrier to generics as well. * AI as sovereign infrastructure. A regulatory framework was put in place to allow defined certain path from AI drug discovery to clinical testing, validated by Insilico programs in China. Mukherjee ends - " Purists will rightly worry about the risks of acceleration. Faster approvals will inevitably lead to more conditional authorisations, greater reliance on surrogate endpoints, and increased pressure on post-market surveillance. Some drugs that reach patients will later disappoint. But this critique misses the larger context. .... If Chinese companies are yet to achieve a defining global win, a first-in-class blockbuster that reshapes a therapeutic category worldwide, the infrastructure for such a win is now operational. Capacity has been built. Incentives are aligned. Speed has been codified. The question is no longer whether China can innovate in the pharmaceutical industry. " My reflection is that a single Centrally controlled government can set up an operating system virtually unopposed- an engineering approach. In the West, patient rights moderate clinical testing and thus produces caution- a legal approach. We live in interesting time for biopharma. https://lnkd.in/ev8x-jzV

Australia approved ~5,000+ clinical trials over the past decade — and global biotech is increasingly using it to generate early clinical data faster and cheaper than the US or EU. The reason is simple: Australia combines rapid approvals, strong hospital networks, and R&D incentives that can refund up to ~43.5% of eligible R&D spend. But after mapping the Australia clinical trials ecosystem, the real insight for me is this: Most founders still think the advantage is just “running a trial in Australia.” It’s not. The startups that benefit most are the ones building across the 6 layers that actually make Australia a clinical trial acceleration system: 1. Research Institutes Where scientific credibility begins. Institutes like Garvan Institute, WEHI, SAHMRI, QIMR Berghofer, Burnet Institute strengthen protocols and investigator alignment. 2. Trial Hospitals Where strategy becomes execution. Sites like Peter MacCallum, Royal Prince Alfred, Royal Melbourne Hospital, Westmead Hospital drive recruitment and trial speed. 3. CRO Platforms Where founders either accelerate or lose months. Companies like Novotech, Avance Clinical, George Clinical, Nucleus Network, Linear Clinical Research move trials from strategy to operations. 4. Funding Programs Often underestimated. Programs like the R&D Tax Incentive, MRFF, NHMRC, MTPConnect, Biomedical Translation Fund help reduce net trial costs. That’s why I don’t see this as just a clinical trial location. I see it as a clinical trial acceleration stack: research → sites → CRO execution → funding → biotech innovation → pharma partnerships And this is where the bottleneck appears. Many biotech startups can show: • strong science • promising early data • interesting therapeutic potential But far fewer can show what investors actually underwrite: • strong KOL alignment • realistic recruitment strategy • CRO readiness • capital-efficient trial design • a credible partnering path That gap is where burn increases and valuations compress. That’s why I built: • the Australia Clinical Trials Acceleration Market Map • a deeper blog post explaining the ecosystem • and a free Clinical Trial Readiness Diagnostic for founders and investors. If you want the visual + blog + free tool, comment AUSTRALIA and I’ll send it over. #ClinicalTrials #Biotech #Australia #DrugDevelopment #LifeSciences #ClinicalResearch #BiotechStartups #HealthTech #MedTech #Pharma #StartupEcosystem #VentureCapital #HealthcareInnovation #GrowthStrategy #GrowthVybz

The pharmaceutical landscape is at a turning point. We're moving beyond experimental chatbots to intelligent agent workflow that actually execute basic workflows from molecular discovery to regulatory submissions. This shift isn't incremental but it is slowly structural. Genentech's CLADD system simulates a virtual advisory board of chemists and biologists, generating valid molecules at machine speed. Sanofi's partnership with OpenAI goes further into mining decades of scientific knowledge to find targets we'd miss manually. We're talking about virtualizing failure to derisk physical experiments. Clinical trials are moving at unprecedented pace. Sanofi's Muse agent creates comprehensive recruitment strategies in minutes instead of months. Novartis accelerated protocol generation by 60%-70%. Takeda cut CSR writing time by half.  When one is dealing with a 9.8-year product lifecycle compressed by regulatory headwinds, every month gained equals hundreds of millions in revenue. Regulatory is becoming strategic as  Pfizer and Takeda report 50-75% reductions in submission timelines. That's not just faster paperwork but that means  earlier market entry and patient access. GSK and Sanofi are building intelligence units that harmonize global regulations in real time, eliminating costly bridging studies. Manufacturing is slowly shifting  from reactive to predictive. Merck's deviation management moves from days to hours. Sanofi's PLAI platform predicted 60% of supply disruptions before they happened. Eli Lilly's partnership with NVIDIA creates digital twins to optimize production in simulation before touching physical lines. The economics are undeniable. McKinsey estimates $60-110 billion in annual value potential. But this requires fundamental changes: such as private AI clouds for IP protection, retrieval augmented generation to prevent hallucination, multi agent architectures that mimic peer review and focus is on building cognitive enterprises. The competitive advantage goes to companies that operationalize the AI Scientist, the Generative Trial or the Cognitive Supply Chain with proper AI Governance , Responsible AI policies and Guardrails. #PharmaceuticalAI #DrugDiscovery #ClinicalTrials #RegulatoryAffairs #SupplyChainOptimization #CognitiveEnterprises #AIScientist #Pharma2025 #LifeSciencesLeadership #DigitalTransformation #PatientAccess #CompetitiveAdvantage #AIAgents Disclaimer: The opinions are mine and not employer's

This initiative reflects a strategic shift toward leveraging large-scale human data to directly accelerate drug discovery and development. While traditional animal models have played a foundational role, they often lack the fidelity needed to fully capture the complexity of human disease. Today, the integration of expansive datasets—from human biobanks, electronic health records, imaging, wearable devices, and naturally occurring human knockouts—enables unprecedented insight into real-world human biology. Critically, this effort is complemented by high-throughput perturbation data from systems like CRISPR screens, transcriptomic profiling, and proteomics, which are essential for mapping causal relationships and validating therapeutic targets at scale. Combined with advanced AI tools like large language models (LLMs), these multidimensional datasets empower researchers to model disease, stratify patients, and predict drug responses with far greater precision. By embracing these human-based technologies, the NIH is not only reducing reliance on animal testing but also accelerating the translation of discovery into meaningful, human-relevant therapeutics. #DataScience #DrugDiscovery #ComputationalBiology #HumanGenetics #HumanBiobank #CRISPRScreens #PrecisionMedicine #WearableData #HighThroughputBiology #TranslationalResearch #DrugDiscovery https://lnkd.in/dSRUCvPh